[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cardiovascular-complications\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cardiovascular-complications":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,53,80],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100562875","the-incidence-of-pulmonary-cardiovascular-and-renal-system-non-communicable-complications-associated-with-the-post-acute-phase-of-the-infection-by-covid-19-100562875",false,"NCT06608849","The Incidence of Pulmonary, Cardiovascular and Renal System Non-communicable Complications Associated With the Post-acute Phase of the Infection by Covid-19","A Non-interventional, Prospective, Cross-sectional Study of the Incidence of Pulmonary, Cardiovascular and Renal System Non-communicable Complications Associated With the Post-acute Phase of the Infection by Sars-Cov-2","POINT","Inclusion Criteria:\n\nGroup A (comparators)\n\n1. Adults (18 years or more) of both genders\n2. Negative history of acute COVID-19\n\nGroup B (patients with ΝΟ dysfunction)\n\n1. Adults (18 years or more) of both genders\n2. History of acute COVID-19 hospitalized or non-hospitalized. All cases appearing from start of the pandemic until the last six months may apply\n3. Absence of any current overt organ dysfunction\n4. Absence of signs of any organ dysfunction during acute COVID-19\n\nGroup C (patients with dysfunctions)\n\n1. Adults (18 years or more) of both genders\n2. History of acute COVID-19 hospitalized or non-hospitalized. All cases appearing from start of the pandemic until the last six months may apply\n3. Presence of signs of organ dysfunction of the lung, the kidneys or the heart during acute COVID-19\n\nExclusion Criteria:\n\nGroup A (comparators)\n\n1. Any other co-existing disorder generating clinical symptoms\n2. Failure to thrive according to the attending physicians\n3. Pregnancy or lactation\n\nGroup B (patients with ΝΟ dysfunction)\n\n1. Any other co-existing disorder generating clinical symptoms\n2. Failure to thrive according to the attending physicians\n3. Pregnancy or lactation\n\nGroup C (patients with dysfunctions)\n\n1. Any other co-existing disorder generating clinical symptoms\n2. Medical history of any of:\n\n   * stage III or IV chronic obstructive pulmonary disease according to the GOLD criteria\n   * pulmonary fibrosis or pulmonary hypertension\n   * stage IV solid tumour malignancy under chemotherapy or radiotherapy\n   * systemic sclerosis\n   * congestive heart failure\n   * stage II, III or IV dyspnoea according to the New York Heart Association classification before the acute COVID-19\n3. Limited chance of survival for at least six months due to co-existing comorbidity(-ies) according to the judgement of the attending physicians\n4. Pregnancy or lactation",true,"ALL","18 Years",{"count":21,"type":22},345,"ESTIMATED","OBSERVATIONAL","More than 660 million cases of COVID-19 have been reported worldwide, with 183 million cases in the EU alone. In several people, after recovery, the effects of the first waves of COVID-19 persisted beyond the acute phase and increased the risk of chronic multiorgan symptoms and disease. Up to 70% of people affected by COVID-19 showed reduced organ function even four months or more after COVID-19 diagnosis. Such a functional decline is associated with an increased risk of the development of non-communicable diseases (NCDs). Thus, there is an essential need for a better knowledge, tools, clinical guidelines and recommendations that it will make it possible to reduce this overrepresentation of NCDs as a consequence of the post-acute phase (PAP) of COVID-19.\n\nThe overall concept underpinning \"POINT\" is to i) build detailed knowledge on the link between the PAP of COVID-19 caused by previous, current, and future SARS-CoV-2 variants in vaccinated and unvaccinated people, and NCDs, ii) identify robust biomarkers and build predictive tools that help early identification and management of risk of NCDs, and iii) develop guidelines and recommendations for all parts of the healthcare value chain, allowing best prevention and care acknowledging vulnerability. The investigators will focus on the NCDs affecting pulmonary, cardiovascular and renal systems.",[26,27,28,29],"Pulmonary Complications","Cardiovascular Complications","Renal Complications","COVID-19",[31,32,33,34,35,36,37,38,39],"Covid-19","SARS-CoV-2","Pulmonary complications","Cardiovascular complications","Renal complications","Post-acute phase","Non communicable diseases","Biomarkers","Prevention","RECRUITING","2025-11-14",{"date":43,"type":44},"2025-11-17","ACTUAL",{"date":46,"type":44},"2024-12-10",{"date":48,"type":22},"2027-11-04",{"name":50,"class":51},"Hellenic Institute for the Study of Sepsis","OTHER",6,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":4},"100600971","an-epidemiological-and-long-term-endpoint-registry-study-on-disease-syndrome-correlation-patterns-in-comorbid-population-with-diabetes-and-ischemic-cardio-cerebrovascular-disease-100600971","NCT07104422","An Epidemiological and Long-Term Endpoint Registry Study on Disease-Syndrome Correlation Patterns in Comorbid Population With Diabetes and Ischemic Cardio-Cerebrovascular Disease","Diabetes","Inclusion Criteria:\n\n* Aged ≥ 18 years Diagnosed with comorbidities relevant to \"toxin-damaged collaterals\" theory (e.g., type 2 diabetes mellitus with cardiovascular\u002Fcerebrovascular disease).\n\nVoluntary participation with signed informed consent.\n\nExclusion Criteria:\n\n* Acute infectious diseases, malignant tumors, or autoimmune disorders. Mental illness or cognitive impairment affecting symptom assessment.",{"count":61,"type":22},12000,"Explore the characteristics of TCM syndrome elements and distribution patterns of syndrome types in comorbid populations; Screen for \"high-risk syndrome patterns\" and frequently co-occurring complex syndromes; Identify characteristic syndrome patterns at key stages: acute phase, recovery phase, and upon occurrence of endpoint events; Investigate the temporal evolution of TCM syndrome patterns and the disease-syndrome correlation patterns in comorbid patients.",[64,27],"Type 2 Diabetes Mellitus (T2DM)",[66,67,68,69],"Diabetes comorbidities","Cardiovascular-cerebrovascular diseases","Real-world registry study","Disease-syndrome correlation","NOT_YET_RECRUITING","2025-07-29",{"date":73,"type":44},"2025-08-05",{"date":75,"type":22},"2025-08-15",{"date":77,"type":22},"2028-07-30",{"name":79,"class":51},"Guangzhou University of Traditional Chinese Medicine",{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":18,"minAge":87,"maxAge":19,"enrollmentInfo":88,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":90,"conditions":91,"keywords":95,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":111},"100500017","vascular-complications-in-children-from-t1d-diagnosis-100500017","NCT05790785","Vascular Complications in Children From T1D Diagnosis","Understanding Vascular Complications in Children From Type 1 Diabetes Diagnosis","Inclusion Criteria\n\n1. Between the ages of 8-18 years\n2. Within 14 weeks of type 1 diabetes diagnosis\n3. Ability and willingness to undergo non-invasive arterial stiffness assessment for 1hr and willingness to wear the 24-h automated blood pressure monitoring (ABPM) device.\n\nExclusion Criteria\n\nChildren will be ineligible to participate in the study if they meet any of the following:\n\n1. Other cardiometabolic or endocrine diseases diagnosis (type 2 diabetes; familial disorders of cholesterol metabolism; lupus)\n2. Other genetic syndromes (Down Syndrome; Prader-Willi)\n3. Eating disorder diagnosis\n4. Transgender children taking hormone blockers or exogenous sex steroids\n5. Currently treated with medications known to affect metabolism (e.g. glucocorticoids, antipsychotics).","8 Years",{"count":89,"type":22},150,"Cardiovascular disease is a complication of type 1 diabetes (T1D), a life-long disease, usually diagnosed in childhood. The goal of this project is to determine the timing and factors leading to vascular damage in children from T1D diagnosis.",[92,27,93,94],"Type 1 Diabetes","Child","Adolescent",[96,97,98,99,38,100,101],"Type 1 diabetes","Children","Arterial stiffness","Body composition","Nutrition","Blood pressure","2025-04-29",{"date":104,"type":44},"2025-05-02",{"date":106,"type":44},"2024-03-25",{"date":108,"type":22},"2027-09-30",{"name":110,"class":51},"University of British Columbia",1]